drugset / Trial / NCT04176835

Oxytocin and Social Decision Making in Schizophrenia

NCT04176835 ↗

Non-randomizedCrossoverSingle-blindOther

Summary

schizophrenia patients and healthy volunteers will be included. Subjects who meet the inclusion and exclusion criteria for the study will be recruited. After completion of clinical assessments and neuropsychological assessments, all subjects will undergo two fMRI scans. In one scan subjects will receive a single dose of intranasal oxytocin and in another scan, they will receive intranasal saline. The order of administration of oxytocin or saline will be counterbalanced so that they are not administered in the same order to all subjects. Subjects will be blind to the drug administered.

Timeline

Start
2016-04
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide — Intranasal

Indications